Core Insights - Prothena Corporation plc announced the resignation of Paula Cobb from its Board of Directors as she will join Manifold Bio as Chief Operating Officer, marking a significant transition for the company [1][2] - Cobb has been a part of Prothena's board for six years, contributing to the company's vision and strategy, and her departure leaves the board with 8 directors [2] Company Overview - Prothena is a late-stage clinical biotechnology company specializing in protein dysregulation, with a pipeline of investigational therapeutics aimed at treating neurodegenerative and rare peripheral amyloid diseases [3] - The company leverages decades of scientific research to advance therapeutic candidates for various indications, including ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, and Parkinson's disease [3]